论文部分内容阅读
目的观察分清化浊胶囊对阿霉素肾病大鼠的影响及其可能的作用机制。方法将雄性SD大鼠随机分为6组(对照组,模型组,阳性对照组,分清化浊胶囊低、中、高剂量组),除对照组外,其余各组大鼠采用尾iv阿霉素法制成阿霉素肾病大鼠模型,第一次尾iv阿霉素(4mg/kg)1周后,第二次iv阿霉素(3.5mg/kg)。造模成功后,对照组和模型组ig生理盐水,阳性对照组ig黄葵胶囊混悬液;其余治疗组ig分清化浊胶囊混悬液。每日一次,疗程4周。观察大鼠一般情况,在给药前、给药7、14、21、28d测定24h尿蛋白定量,末次给药后,测定大鼠血清总蛋白(TP)、白蛋白(ALB)、总胆固醇(TC)、三酰甘油(TG)、血尿素氮(BUN)、肌酐(Cr),并观察大鼠肾脏病理变化。结果治疗前,与对照组比较,各治疗组尿蛋白定量有显著差异(P<0.01),说明造模成功;阳性组、分清化浊胶囊各剂量组均能显著降低尿蛋白(P<0.01)。与模型组比较,分清化浊胶囊高、中剂量能升高TP、ALB水平(P<0.01)。分清化浊胶囊高、中剂量对TG及TC有降低作用(P<0.01)。各治疗组对肾功能指标BUN、Cr无明显影响。各治疗组肾脏病变程度较模型组有明显减轻。结论分清化浊胶囊可以显著降低阿霉素肾病大鼠尿蛋白、TC、TG;明显升高阿霉素肾病大鼠TP、ALB水平,减轻肾脏病理损害。
Objective To observe the effect and mechanism of Fenhua capsule on adriamycin-induced nephropathy in rats. Methods Male Sprague-Dawley rats were randomly divided into 6 groups (control group, model group, positive control group, sub-Qinghuazao capsule low, medium and high dose groups). Except the control group, Suginu method made adriamycin nephropathy rat model, the first tail iv doxorubicin (4mg / kg) after 1 week, the second iv doxorubicin (3.5mg / kg). After successful modeling, the control group and model group ig saline, positive control group ig the yellow capsule capsule suspension; the other treatment group ig Fenghua capsule capsule. Once daily, for 4 weeks. The general conditions of rats were observed. The urinary protein excretion was measured 24h, 14, 21, 28d before administration, and the serum levels of TP, ALB, TC), triglyceride (TG), blood urea nitrogen (BUN) and creatinine (Cr) were measured. The renal pathological changes were observed. Results Before treatment, the urinary protein in each treatment group was significantly different (P <0.01) compared with the control group, indicating that the model was successful. . Compared with model group, high and medium doses of Qinghuazao capsule can increase TP and ALB levels (P <0.01). The results showed that high and middle doses of Qingzhuo Capsule had a lower effect on TG and TC (P <0.01). The treatment group on renal function indicators BUN, Cr had no significant effect. The degree of renal disease in each treatment group was significantly reduced compared with the model group. Conclusions Qingzhuo Capsule can significantly reduce urinary protein, TC, TG in rats with adriamycin-induced nephropathy, significantly increase TP and ALB levels in rats with adriamycin-induced nephropathy, and reduce renal pathological damage.